Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
PaperCitations, authors & open-access status
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 655 citations, 2023 year and green oa status.
655
Citations
2023
Year
green
OA Status